alectinib
Selected indexed studies
- Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. (N Engl J Med, 2024) [PMID:38598794]
- Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. (N Engl J Med, 2017) [PMID:28586279]
- Alectinib. (Recent Results Cancer Res, 2018) [PMID:30069772]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. (2024) pubmed
- Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. (2017) pubmed
- Alectinib. (2018) pubmed
- Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study. (2026) pubmed
- Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. (2017) pubmed
- Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. (2019) pubmed
- Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial. (2023) pubmed
- Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. (2019) pubmed
- Alectinib-induced hemolytic anemia. (2023) pubmed
- Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer. (2022) pubmed